Gilead, Seattle
Gilead lays off 72 workers in Seattle, plans to shutter R&D support site
Roughly a year ago, Gilead Sciences revealed that it was laying off about 7% of Kite Pharma’s workforce in a bid to refresh its cell therapy subsidiary. | Gilead will lay off 72 staffers in Seattle, the company confirmed Thursday.
COVID drugmaker to close Seattle office, laying off 72 workers
The Washington State Employment Security Department said in the filing that 72 employees will be laid off on Jan. 17. A Gilead spokesperson said in an emailed statement that some teams will be moved to other offices outside of Seattle.
Biotech giant Gilead Sciences to close its Seattle office, lay off employees
Global biopharmaceutical company Gilead Sciences Inc. (Nasdaq: GILD) is closing its office in Seattle and laying off 72 employees, according to a Washington state Worker Adjustment and Retraining Notification filed on Wednesday.
Zacks.com on MSN15h
Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a BetWhen deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often ...
Hosted on MSN16h
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should KnowGilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Wolfe Research initiated coverage of Gilead (GILD) with an Outperform rating and $110 price target Gilead’s bread and butter has been ...
Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...
Gilead Sciences ( GILD) increased its growth forecast for the year on strong third quarter results, marking a shift away from ...
TD Cowen analyst Tyler Van Buren maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of ...
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
Data shows Latino and Black people make up nearly 30% of the Bay Area population but only about 10% of active medical ...
Citi has started coverage of Gilead Sciences (NASDAQ:GILD) and Vertex Pharmaceuticals (NASDAQ:VRTX) at buy saying the former will benefit from short-term growth of Biktarvy (bictegravir, emtricitabine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback